Wie Silibinin das Hepatitis-C-Virus bekämpft

Zusammenfassung

Der Mariendistelextrakt Silymarin wird seit dem Altertum als Hepatoprotektivum verwendet. Vor ein paar Jahren wurde die Fachwelt in Erstaunen versetzt, als im Rahmen einer klinischen Studie überraschend gezeigt wurde, dass der Silymarin-Bestandteil Silibinin einen ausgeprägten antiviralen Effekt bei Patienten mit chronischer Hepatitis C aufweist. Der zugrunde liegende Wirkmechanismus ist bis heute nicht vollständig aufgeklärt. Allerdings liegt eine Reihe von präklinischen Daten vor, die zu verschiedenen Hypothesen geführt haben, wie Silibinin mit dem Hepatitis-C-Virus während des Reproduktionszyklus interagiert.

Summary

How silibinin fights the hepatitis C virus
Silymarin extracted from milk thistle fruits has been used as a hepatoprotective drug since ancient times. A few years ago first clinical data emerged showing pronounced antiviral activity against hepatitis C virus (HCV) for silibinin, a silymarin component. The mechanisms by which HCV suppression occurs have not been fully characterized yet. A substantial amount of data has been produced leading to various hypotheses on how silibinin interacts with the HCV reproductive cycle.

Schlüsselwörter

Mariendistel - Silybum marianum (L.) Gaertn. - Silymarin - Silibinin - Hepatitis C - HCV - Wirkmechanismus

Key words

Milk thistle - Silybum marianum (L.) Gaertn. - silymarin - silibinin - hepatitis C - HCV - mechanism of action

• Literatur

• 1 Saller R, Brignoli R, Melzer J et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15: 9-20
• 2 Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hep 2005; 12: 559-567
• 3 Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567
• 4 Wagoner J, Morishima C, Graf TN et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One 2011; 6: e16464
• 5 Morishima C, Shuhart MC, Wang CC et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010; 138: 671-681
• 6 Blaising J, Lévy PL, Gondeau C et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol 2013; doi: 10.1111/cmi.12155. [Epub ahead of print]
• 7 Ahmed-Belkacem A, Ahnou N, Barbotte L et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138: 1112-1122
• 8 Polyak SJ, Oberlies NH, Pécheur EI et al. Silymarin for HCV infection. Antivir Ther 2013; 18: 141-147
• 9 Esser-Nobis K, Romero-Brey I, Ganten TM et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 2013; 57: 953-963
• 10 Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849
• 11 Guedj J, Dahari H, Pohl RT et al. Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56: 1019-1024
• 12 Calland N, Dubuisson J, Rouillé Y et al. Hepatitis C virus and natural compounds: a new antiviral approach?. Viruses 2012; 4: 2197-2217
• 13 Polyak SJ, Ferenci P, Pawlotsky JM. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology 2013; 57: 1262-1271
• 14 Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013; 369: 321-342
• 15 Gane EJ, Roberts SK, Stedman CA et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376 (9751) 1467-1475
• 16 Sarrazin C, Hézode C, Zeuzem S et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 (Suppl. 1) S88-100